Poland· PL-100524432
Yeytuo
A lenacapavir product containing lenacapavirum, registered in Poland by Gilead Sciences Ireland UC. The same ATC class is registered in 15 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Lenacapavir is registered in 15 of 19 countries.
Countries holding a registration under ATC J05AX31 (lenacapavir), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Lenacapavir · ATC J05AX31
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lenacapavir costs, country by country.
Normalised to the WHO defined daily dose (0.19 g), the median price runs from $0.45 in France to $511.10 in Switzerland — a ×1140 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lenacapavir · price per daily dose (0.19 g)
USD · FX 28 Sept 2026
- CH Switzerland$511.10
- FR France$0.45
The record
At a glance
URPL (Poland)- Active substance
- Lenacapavirum
- Manufacturer
- Gilead Sciences Ireland UC
- Country
- Poland (PL)
- ATC code
- J05AX31
- ATC class
- Lenacapavir
- Defined daily dose
- 0.19 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lenacapavir in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IcelandSunlencaGilead Sciences Ireland UC*
- CzechiaSUNLENCAGilead Sciences Ireland UC, Carrigtohill
- BelgiumSunlenca 464 mgGilead Sciences Ireland UC
- SwedenSunlenca 464 mg Injektionsvätska, lösningGilead Sciences Ireland UC
- NorwaySunlencaGilead Sciences Ireland UC
- SpainSUNLENCA 464 MG SOLUCION INYECTABLEGilead Sciences Ireland Unlimited Company
- United StatesSunlencaGilead Sciences, Inc.
- FinlandSunlencaGilead Sciences Ireland UC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Sunlenca, Yeytuo
- Liechtenstein · Sunlenca, Yeytuo
- Norway · Sunlenca, Yeytuo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/be6465d6-df7b-4d6f-9b68-1bf4c96c2e18 GET /v1/drugs/be6465d6-df7b-4d6f-9b68-1bf4c96c2e18?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "464 mg",
"packaging": "Rpz ¦ EU/1/25/1976/002 ¦ 163610\n2 fiol. 1,5 ml ¦ 2 igły do pobrania ¦ 2 igły z zabezpieczeniem",
"substance": "Lenacapavirum 464 mg",
"common_name": "Lenacapavirum",
"pl_product_id": "100524432",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about lenacapavir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.